Geron is engaged in the development of innovative medicines for myeloid hematologic malignancies. The company focuses on research and development, particularly in telomerase inhibition.

Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

COM:GERON

Geron

Last Close

4.02

22/11 21:00

Market Cap

2.73B

Beta: -

Volume Today

6.85M

Avg: -

Filings Not Available